ScoreComparison
Why is Nektar Therapeutics ?
1
Poor long term growth as Net Sales has grown by an annual rate of -17.45% and Operating profit at 10.40% over the last 5 years
2
The company has declared negative results in Mar'2025 after 2 consecutive positive quarters
- NET SALES(Q) At USD 11.79 MM has Fallen at -37.06%
- INTEREST(Q) At USD 6.05 MM has Grown at 12.11%
- CASH AND EQV(HY) Lowest at USD 446.11 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 447.00%, its profits have risen by 21.5%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Nektar Therapeutics for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Nektar Therapeutics
463.05%
0.24
1235.60%
S&P 500
14.9%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-17.45%
EBIT Growth (5y)
10.40%
EBIT to Interest (avg)
-7.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-8.04
Sales to Capital Employed (avg)
0.48
Tax Ratio
0.12%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
24.82
EV to EBIT
-14.22
EV to EBITDA
-14.34
EV to Capital Employed
-22.09
EV to Sales
30.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-139.41%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at USD -76.53 MM
RAW MATERIAL COST(Y)
Fallen by -20.74% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 36.69 times
-16What is not working for the Company
NET SALES(Q)
At USD 11.79 MM has Fallen at -37.06%
INTEREST(Q)
At USD 6.05 MM has Grown at 12.11%
CASH AND EQV(HY)
Lowest at USD 446.11 MM
INVENTORY TURNOVER RATIO(HY)
Lowest at 0 times
PRE-TAX PROFIT(Q)
At USD -34.88 MM has Fallen at -22.62%
Here's what is working for Nektar Therapeutics
Net Profit
Higher at USD -76.53 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 36.69 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -20.74% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Nektar Therapeutics
Net Sales
At USD 11.79 MM has Fallen at -37.06%
over average net sales of the previous four periods of USD 18.73 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Interest
At USD 6.05 MM has Grown at 12.11%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Pre-Tax Profit
At USD -34.88 MM has Fallen at -22.62%
over average net sales of the previous four periods of USD -28.45 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Cash and Eqv
Lowest at USD 446.11 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Inventory Turnover Ratio
Lowest at 0 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
